Growth Factor News and Research

RSS

Low dose carbon monoxide therapy can prevent fetal death

Heme oxygenase-1 is essential for the growth of blood vessels in the placenta and in establishing blood flow in the umbilical cord. Too little HO-1 can lead to a restriction in the growth of the fetus and even in fetal death and miscarriage. New research published in BioMed Central's open access journal Medical Gas Research has shown that low dose carbon monoxide therapy is able to restore placental function and prevent fetal death in mice, without any detrimental effects.

19 Feb 2012

New UTA method shows promise against heart disease

University of Texas at Austin researchers have demonstrated a new and more effective method for regrowing blood vessels in the heart and limbs - a research advancement that could have major implications for how we treat heart disease, the leading cause of death in the Western world.

17 Feb 2012

New potential strategy for KRAS-mutant colon cancers

Researchers from the Massachusetts General Hospital (MGH) Cancer Center have identified a new potential strategy for treating colon tumors driven by mutations in the KRAS gene, which usually resist both conventional and targeted treatments.

17 Feb 2012

Researchers test nanoscale carbon clusters for cancer chemotherapy

A mixture of current drugs and carbon nanoparticles shows potential to enhance treatment for head-and-neck cancers, especially when combined with radiation therapy, according to new research by Rice University and the University of Texas MD Anderson Cancer Center.

16 Feb 2012

Acorda's fourth quarter GAAP net income increases to $12.7 million

Acorda Therapeutics, Inc. today announced its financial results for the fourth quarter and full year ended December 31, 2011.

16 Feb 2012

HB-EGF plays a critical role during retina regeneration

University of Michigan Health System research into the mechanisms by which zebrafish are able to regenerate damaged retinas after injury suggests new strategies for one day being able to do the same in humans - potentially allowing doctors to slow or reverse conditions like macular degeneration and glaucoma.

15 Feb 2012

Researchers pinpoint source of Loeys-Dietz syndrome

A USC research team has pinpointed the source of a genetic disorder that causes life-threatening birth defects, which may allow doctors to quickly diagnose and better treat the disease.

14 Feb 2012

Regeneron reports total revenues of $123.0M for fourth quarter 2011

Regeneron Pharmaceuticals, Inc. announced financial and operating results for the fourth quarter and full year 2011 and provided an update on development programs.

13 Feb 2012

FGF21 hormone causes significant and rapid bone loss in mice

An endocrine hormone used in clinical trials as an anti-obesity and anti-diabetes drug causes significant and rapid bone loss in mice, raising concerns about its safe use, UT Southwestern Medical Center researchers have shown.

7 Feb 2012

Three new targeted drugs can lead to fatal cancer complications

Treatment with three relatively new "targeted" cancer drugs has been linked to a slightly elevated chance of fatal side effects, according to a new analysis led by scientists at Dana-Farber Cancer Institute. They added that the risk remains low, but should be taken into account by physicians and patients.

7 Feb 2012

Inhibiting MET signaling in glioblastoma has major therapeutic value

A recent discovery by Van Andel Research Institute (VARI) scientists enables the prediction of patient sensitivity to proposed drug therapies for glioblastoma - the most common and most aggressive malignant brain tumor in humans.

7 Feb 2012

Vigorous exercise triggers MSC accumulation in skeletal muscle

University of Illinois researchers determined that an adult stem cell present in muscle is responsive to exercise, a discovery that may provide a link between exercise and muscle health. The findings could lead to new therapeutic techniques using these cells to rehabilitate injured muscle and prevent or restore muscle loss with age.

6 Feb 2012

Molecular subtypes of lung cancer manifest as different diseases

Different kinds of lung cancer behave in different ways, suggesting they are fundamentally different diseases. According to a University of Colorado Cancer Center study published in Cancer, the official journal of the American Cancer Society, different subgroups of non-small cell lung cancer (NSCLC) show distinct patterns of spread in the body.

3 Feb 2012

Researchers reveal how antipsychotics affect metabolism by SMAD3 activation

In a paper published January 31 in the journal Molecular Psychiatry, researchers at Sanford-Burnham Medical Research Institute (Sanford-Burnham) reveal how antipsychotic drugs interfere with normal metabolism by activating a protein called SMAD3, an important part of the transforming growth factor beta (TGFbeta) pathway.

2 Feb 2012

USF receives DOD grant for battlefield-related TBI research

The University of South Florida (USF) has received a $1.57 million U.S. Department of Defense grant to conduct translational research on traumatic brain injury and other battlefield related injuries and diseases.

2 Feb 2012

Study finds sharp increase in BMP use for spinal fusion surgery

The use of bone morphogenetic protein (BMP) for spinal fusion surgery has risen sharply over the past decade, increasing costs with no evidence of improved outcomes, reports study in the February 1 issue of Spine.

1 Feb 2012

Circadian's VGX-100 human antibody improves corneal graft survival

Circadian Technologies Limited announced today the publication of data in the scientific journal, Investigative Ophthalmology & Visual Science (IOVS), showing that VEGF-C expression is markedly up-regulated in corneal graft rejection.

30 Jan 2012

Boehringer Ingelheim initiates two afatinib phase III trials in head and neck cancer

Boehringer Ingelheim announced today the initiation of two phase III clinical trials, LUX-Head & Neck 1 and LUX-Head & Neck 2. These trials evaluate afatinib in patients with metastatic and recurrent head and neck cancer, and in patients with locally advanced disease, respectively.

27 Jan 2012

Study describes new pharmacological resistance to colon cancer

Doctors and researchers of Hospital del Mar and its research institute, the IMIM, have lead a study describing a new pharmacological resistance to cancer. This new mechanism is a mutation in an oncogene called EGFR (epidermal growth factor receptor) causing resistance to treatment using a drug called cetuximab, a monoclonal antibody which specifically attacks the EGFR.

23 Jan 2012

Combination of gefitinib and miRNA-inhibitor might effectively treat NSCLC

New research published in Nature Medicine indicates that targeted drugs such as gefitinib might more effectively treat non-small cell lung cancer if they could be combined with agents that block certain microRNAs.

20 Jan 2012